| Quarterly Financials | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 54 | 116 | 103 | 116 | 126 | 116 | 114 | 119 | 107 | 124 | 117 | 126 | 127 | 146 | 138 | 159 | 160 | 188 | 174 | 179 | 195 | 208 | 210 |
| Expenses | 38 | 62 | 54 | 58 | 66 | 62 | 63 | 68 | 65 | 72 | 69 | 72 | 73 | 82 | 82 | 92 | 95 | 107 | 102 | 105 | 115 | 120 | 119 |
| EBITDA | 16 | 54 | 49 | 59 | 60 | 54 | 51 | 51 | 43 | 52 | 48 | 54 | 54 | 64 | 55 | 66 | 65 | 81 | 72 | 73 | 81 | 88 | 91 |
| Operating Profit % | 27 % | 45 % | 46 % | 49 % | 46 % | 45 % | 43 % | 41 % | 38 % | 40 % | 39 % | 41 % | 40 % | 41 % | 38 % | 41 % | 39 % | 42 % | 40 % | 39 % | 39 % | 41 % | 42 % |
| Depreciation | 12 | 14 | 13 | 13 | 12 | 13 | 13 | 15 | 14 | 16 | 20 | 11 | 13 | 14 | 15 | 16 | 17 | 17 | 18 | 19 | 21 | 22 | 24 |
| Interest | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 |
| Profit Before Tax | 1 | 36 | 33 | 43 | 44 | 38 | 34 | 31 | 24 | 31 | 22 | 37 | 36 | 45 | 35 | 44 | 42 | 57 | 47 | 47 | 52 | 58 | 58 |
| Tax | -1 | 9 | 8 | 11 | 11 | 10 | 8 | 8 | 6 | 8 | 6 | 9 | 9 | 11 | 9 | 10 | 10 | 15 | 11 | 13 | 14 | 15 | 15 |
| Net Profit | 2 | 27 | 25 | 32 | 33 | 28 | 26 | 24 | 18 | 24 | 17 | 28 | 26 | 34 | 26 | 34 | 32 | 42 | 35 | 35 | 39 | 43 | 43 |
| EPS in ₹ | 3.55 | 2.59 | 2.43 | 3.08 | 3.23 | 2.72 | 2.48 | 2.33 | 1.71 | 2.29 | 1.60 | 2.69 | 2.57 | 3.26 | 2.53 | 3.27 | 3.06 | 4.10 | 3.42 | 3.38 | 3.76 | 4.21 | 4.20 |
Vijaya Diagnostic Centre
Vijaya Diagnostic Centre
1,013.05
+4.15
(0.41%)
Market Cap
10,406.55 Cr
PE Ratio
64.92
Volume
51,578.00
Day High - Low
1,025.00 - 1,004.90
52W High-Low
1,180.00 - 813.15
Key Fundamentals
Market Cap
10,406.55 Cr
EPS
13.95
PE Ratio
64.92
PB Ratio
12.00
Book Value
82.19
EBITDA
291.50
Dividend Yield
0.20 %
Industry
Healthcare Services Sector
Healthcare Service Provider Return on Equity
17.99
Debt to Equity
0.40
Analyst Rating and Forecast
- By Refinitiv from8 analysts
Actual
Company News
View All News
US-based Wasatch Advisors LP sold 23,608 shares of Vijaya Diagnostic Centre Ltd through open market transactions, reducing its shareholding from 3.769% to 3.746% as per SEBI disclosure.
Vijaya Diagnostic Centre Limited has made available the audio recording of its Q3FY26 earnings conference call held on February 13, 2026, following the declaration of unaudited financial results for the quarter ended December 31, 2025.
Vijaya Diagnostic Centre Limited has scheduled a board meeting on February 13, 2026, to consider and approve Q3FY26 unaudited financial results for the quarter ended December 31, 2025.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,396.00 | #1 23,390.12 | 44.13 | #1 2,554.80 | 11.28 | #1 492 | -6.83 | 43.89 | |
1,013.05 | #2 10,406.55 | #9 64.92 | #7 699.70 | #4 23.06 | #3 144 | #7 22.38 | 54.68 | |
1,941.60 | 10,061.76 | 57.04 | 1,346.30 | 10.64 | 146 | 33.65 | 52.37 | |
410.40 | 6,532.00 | 46.66 | 702.20 | 20.80 | 91 | 47.37 | 45.57 | |
567.30 | 5,692.33 | 78.62 | 769.90 | 33.97 | 67 | 60.20 | 59.57 | |
637.90 | 2,069.26 | 25.91 | 742.70 | 16.70 | 78 | -21.13 | 27.79 | |
285.05 | 1,484.56 | 45.33 | 255.90 | 15.11 | 31 | 20.00 | 58.30 | |
711.65 | 1,390.81 | #1 23.51 | 147.80 | #1 134.60 | 19 | #1 520.00 | 58.53 | |
1,600.00 | 1,373.22 | 23.79 | 111.60 | 28.72 | 48 | 65.93 | 51.01 | |
286.75 | 912.17 | 31.35 | 1,170.80 | -18.47 | -134 | 101.06 | 39.86 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
23.06 %
Net Income Growth
20.23 %
Cash Flow Change
22.46 %
ROE
-0.77 %
ROCE
-1.44 %
EBITDA Margin (Avg.)
-1.98 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 234 | 301 | 482 | 541 | 714 | 853 | 983 | 1,274 |
| Fixed Assets | 119 | 151 | 272 | 268 | 371 | 524 | 742 | 865 |
| Current Assets | 103 | 138 | 186 | 239 | 270 | 276 | 211 | 307 |
| Capital Work in Progress | 3 | 3 | 10 | 9 | 34 | 28 | 9 | 70 |
| Investments | 73 | 69 | 55 | 28 | 54 | 139 | 109 | 185 |
| Other Assets | 39 | 78 | 146 | 236 | 255 | 163 | 123 | 154 |
| Total Liabilities | 234 | 301 | 482 | 541 | 714 | 853 | 983 | 1,274 |
| Current Liabilities | 40 | 50 | 59 | 44 | 66 | 66 | 73 | 163 |
| Non Current Liabilities | 33 | 40 | 150 | 138 | 178 | 241 | 250 | 312 |
| Total Equity | 161 | 211 | 274 | 359 | 470 | 547 | 660 | 799 |
| Reserve & Surplus | 155 | 204 | 270 | 355 | 458 | 535 | 647 | 786 |
| Share Capital | 5 | 5 | 5 | 5 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -44 | -7 | 46 | -49 | 4 | 13 | -2 | -9 |
| Investing Activities | -98 | -90 | -31 | -130 | -123 | -110 | -141 | -182 |
| Operating Activities | 62 | 91 | 106 | 130 | 158 | 165 | 183 | 225 |
| Financing Activities | -8 | -7 | -30 | -49 | -31 | -42 | -45 | -52 |
Share Holding
| % Holding | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
| Promoter | 60.00 % | 54.78 % | 54.78 % | 54.78 % | 55.04 % | 55.01 % | 55.01 % | 55.01 % | 54.98 % | 54.90 % | 54.87 % | 54.06 % | 53.93 % | 53.91 % | 53.91 % | 53.05 % | 52.63 % | 52.60 % | 52.60 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 20.09 % | 20.08 % | 18.14 % | 17.54 % | 19.36 % | 19.56 % | 18.27 % | 15.10 % |
| DIIs | 0.00 % | 14.09 % | 13.30 % | 12.88 % | 12.76 % | 15.28 % | 14.23 % | 13.90 % | 19.03 % | 17.99 % | 19.55 % | 20.80 % | 21.49 % | 23.46 % | 24.63 % | 23.72 % | 24.07 % | 25.34 % | 28.59 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 5.45 % | 3.71 % | 3.82 % | 4.00 % | 4.97 % | 5.18 % | 5.13 % | 5.03 % | 5.06 % | 4.63 % | 4.38 % | 3.98 % | 3.94 % | 3.43 % | 3.42 % | 3.24 % | 3.20 % | 3.14 % |
| Others | 40.00 % | 25.68 % | 28.21 % | 28.52 % | 28.20 % | 24.74 % | 25.58 % | 25.96 % | 20.96 % | 22.05 % | 20.95 % | 0.67 % | 0.52 % | 0.55 % | 0.49 % | 0.45 % | 0.50 % | 0.59 % | 0.57 % |
| No of Share Holders | 7 | 2,34,724 | 82,139 | 79,021 | 77,229 | 76,985 | 79,059 | 76,532 | 73,850 | 72,795 | 66,204 | 66,724 | 62,415 | 62,258 | 60,952 | 66,891 | 62,115 | 58,994 | 57,784 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1 | 1 | 1 | 2 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 | 0.16 | 0.1 | 0.2 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 21 Sept 2022 |  Dividend | ₹ 1.00 /share | 20 Sept 2022 | 389.20 | 402.80 |
| 13 Sept 2023 | Dividend | ₹ 1.00 /share | 13 Sept 2023 | 376.05 | 473.60 |
| 30 Aug 2024 | Dividend | ₹ 1.00 /share | 30 Aug 2024 | 666.05 | 892.05 |
| 06 Sept 2024 |  Annual General Meeting | NA | 06 Sept 2024 | 819.80 | 947.20 |
| 07 Nov 2024 |  Quarterly Result Announcement | NA | 07 Nov 2024 | 934.40 | 980.25 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,160.00 | 1,078.50 |
| 25 Apr 2025 |  Extraordinary General Meeting | NA | 25 Apr 2025 | 1,050.75 | 1,061.80 |
| 12 May 2025 | Quarterly Result Announcement | NA | 12 May 2025 | 1,018.20 | 993.10 |
| 28 Jul 2025 | Quarterly Result Announcement | NA | 28 Jul 2025 | 1,045.40 | 1,070.30 |
| 29 Aug 2025 | Dividend | ₹ 2.00 /share | 29 Aug 2025 | 993.10 | 993.45 |
| 05 Sept 2025 | Annual General Meeting | NA | 05 Sept 2025 | 1,050.00 | 1,089.40 |
| 04 Nov 2025 | Quarterly Result Announcement | NA | 04 Nov 2025 | 989.40 | 1,019.70 |
| 25 Nov 2025 |  Merger - Demerger | 22:1 | 25 Nov 2025 | 1,029.00 | 1,029.00 |
| 13 Feb 2026 | Quarterly Result Announcement | NA | 13 Feb 2026 | 970.40 | 994.55 |
Announcements
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome9 days ago
9 days agoAppointment Of Mr. Ankit Shah As A Chief Financial Officer (CFO) Of The Company W.E.F. Feb 13 202610 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Change in Directorate10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Change in Management10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoBoard Meeting Outcome for Outcome Of The Board Meeting Held On Feb 13 202610 days ago
10 days agoUnaudited Financial Results For The Third Quarter And Nine Months Ended December 31 202510 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 09, 2026
Feb 09, 2026Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Quarter And Nine Months Ended December 31 2025.Feb 06, 2026
Feb 06, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 28, 2026
Jan 28, 2026Announcement under Regulation 30 (LODR)-AllotmentJan 08, 2026
Jan 08, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 02, 2026
Jan 02, 2026Closure of Trading WindowDec 24, 2025
Dec 24, 2025Cancellation Of Analyst / Institutional Investor Meeting Dated December 08 2025.Dec 05, 2025
Dec 05, 2025Reply On Clarification Sought By BSE Limited Regarding Increase In The Volume Of The Security Across Exchanges.Dec 05, 2025
Dec 05, 2025Clarification sought from Vijaya Diagnostic Centre LtdDec 05, 2025
Dec 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 24, 2025
Nov 24, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 04, 2025
Nov 04, 2025Noting Of Wholly Owned Subsidiary - Medinova Millennium MRI Services LLP Pursuant To Scheme Of AmalgamationNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Scheme of ArrangementNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationNov 04, 2025
Nov 04, 2025Corporate Action - Fixation Of Record Date On November 25 2025.Nov 04, 2025
Nov 04, 2025Unaudited Financial Results For The Second Quarter And Half Year Ended September 30 2025.Nov 04, 2025
Nov 04, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On Nov 04 2025Nov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 29, 2025
Oct 29, 2025Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Is Scheduled On 04/11/2025 Inter Alia To Consider And Approve The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Second Quarter And Half Year EOct 27, 2025
Oct 27, 2025Announcement under Regulation 30 (LODR)-Change in ManagementOct 18, 2025
Oct 18, 2025Announcement under Regulation 30 (LODR)-Scheme of ArrangementOct 18, 2025
Oct 18, 2025Announcement under Regulation 30 (LODR)-Scheme of ArrangementOct 16, 2025
Oct 16, 2025Shareholders Communication Relating To Saksham Niveshak CampaignOct 08, 2025
Oct 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 03, 2025
Oct 03, 2025Resignation Of Vice President - Operations (Mr. V. Siva Rama Raju Vegesna)Oct 01, 2025
Oct 01, 2025Announcement under Regulation 30 (LODR)-Scheme of ArrangementSep 29, 2025
Sep 29, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Rumour verification - Regulation 30(11)Sep 20, 2025
Sep 20, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 19, 2025
Sep 19, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 06, 2025
Sep 06, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 05, 2025
Sep 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Weblink Letter To Shareholders - As Per Regulation 36(1)(B) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 13, 2025
Aug 13, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 53.53
ATR(14)
Less Volatile 28.89
STOCH(9,6)
Neutral 66.41
STOCH RSI(14)
Neutral 72.89
MACD(12,26)
Bullish 4.30
ADX(14)
Weak Trend 15.23
UO(9)
Bearish 56.03
ROC(12)
Uptrend And Accelerating 2.95
WillR(14)
Neutral -31.43
About Vijaya Diagnostic Centre
Vijaya Diagnostic Centre Limited is an Indian company founded in 1981 and incorporated in 2002. It is the largest integrated diagnostic chain in South India, providing a comprehensive range of diagnostic services including pathological investigations, radiology, nuclear medicine, and related healthcare services. The company operates over 121 diagnostic centers across...more
Listing Date
14 Sept, 2021(4 Years,
40 days)
Chairperson NameSura Surendranath Reddy
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
